Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Oncologist
; 28(6): 520-530, 2023 06 02.
Article
em En
| MEDLINE
| ID: mdl-36971492
ABSTRACT
BACKGROUND:
Since Food and Drug Administration approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (Aâ +â CHP) as initial therapy for previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), there has been limited research on real-world patient characteristics, treatment patterns, and clinical outcomes.METHODS:
We retrospectively analyzed claims of patients with PTCL treated with frontline Aâ +â CHP or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) using the Symphony Health Solutions database. Adults with International Classification of Diseases-9/10 PTCL diagnosis codes who initiated Aâ +â CHP or CHOP between November 2018 and July 2021 were included. A 11 propensity score matching analysis was performed that adjusted for potential confounders between groups.RESULTS:
A total of 1344 patients were included (Aâ +â CHP, nâ =â 749; CHOP, nâ =â 595). Before matching, 61% were men; median age at index was 62 (Aâ +â CHP) and 69 (CHOP) years. The most common Aâ +â CHP-treated PTCL subtypes were systemic anaplastic large cell lymphoma (sALCL; 51%), PTCL-not otherwise specified (NOS; 30%), and angioimmunoblastic T-cell lymphoma (AITL; 12%); the most common CHOP-treated subtypes were PTCL-NOS (51%) and AITL (19%). After matching, similar proportions of patients treated with Aâ +â CHP and CHOP received granulocyte colony-stimulating factor (89% vs. 86%, Pâ =â .3). Fewer patients treated with Aâ +â CHP received subsequent therapy than CHOP overall (20% vs. 30%, Pâ <â .001) and specifically with the sALCL subtype (15% vs. 28%, Pâ =â .025).CONCLUSIONS:
Characteristics and management of this real-world PTCL population who were older and had a higher comorbidity burden than that in the ECHELON-2 trial demonstrate the importance of retrospective studies when assessing the impact of new regimens on clinical practice.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Células T Periférico
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Oncologist
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos